General Dermatology

Dermatology Times is looking back on the top stories in dermatology from the month of May.

A review in JEADV Clinical Practice argues that deliberate nail examination in children can generate and narrow a differential diagnosis across virtually every organ system.

At 6-month follow-up, no behavioral outcomes — including sunscreen use, hat use, or reapplication — showed statistically significant improvement over baseline levels.

Apogee plans to initiate 3 phase 3 trials of zumilokibart in moderate to severe atopic dermatitis—ADventure 1, ADventure 2, and ADventure TCS—in the second half of 2026.

Dermatologists are increasingly integrating AI into clinical workflows, though many still use it primarily as a search tool rather than a true care-support system.

Kathleen Moe, MD, discusses why operational dysfunction, not medicine itself, is driving physician exhaustion in dermatology and beyond.

The findings suggest tetracycline activity may vary depending on drug concentration and local tissue exposure.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

The proposed rule, first introduced in 2015, aimed to prohibit indoor tanning for individuals under 18 because of the known cancer risks associated with UV radiation.

Treatment discontinuations due to laboratory abnormalities were uncommon, occurring in 0.7% of patients at week 52 and remaining below 2% through week 140.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Can "slugging" with petroleum jelly improve skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Despite rapid market growth, many regenerative aesthetic products lack the rigorous nonclinical and clinical safety data that regulators typically require.

Researchers found that adult patients with suspected but unconfirmed HS were more likely to receive symptom-targeted treatment rather than comprehensive disease management.

Emma Guttman-Yassky, MD, PhD, discusses findings from an abrocitinib on-off JADE REGIMEN analysis and what they may mean for disease modification in atopic dermatitis.

Real clinical case scenarios with progressive diagnostic clues challenge dermatology clinicians to think on their feet, sharpen their diagnostic reasoning, and apply practice-changing takeaways at the point of care.

Investigators reported that individualized adalimumab dose adjustments based on serum drug levels could increase clinical response rates compared with standard dosing.

Translational Takeaways distills the most clinically relevant findings from emerging dermatology research into clear, practice-focused insights that inform real-world decision-making.

Can a Mediterranean diet clear skin, or is it just a myth? Read more about the latest social media trend and learn how to counsel your patients in the clinic.

Data show that upadacitinib reduces systemic inflammatory burden in AD, including hs-CRP, a biomarker validated as an independent predictor of major cardiovascular events.

Learn how a specialized financial partner can enable independent practices to navigate market pressures while expanding access and boosting performance.

Recent research on orchid-derived skin care reveals antioxidant, anti-inflammatory, and wound-healing potential, but major gaps in clinical proof and safety reporting remain.

Turmeric and curcumin supplements used for hair loss are increasingly associated with rare but serious cases of liver injury.

Cold atmospheric plasma eases stubborn oral lichen planus in long follow-up study, with a new scoring system tracking pain, function, and healing.

The high-dose D-MNA cohort showed continued improvement from Day 29 to Day 57, a trajectory not observed in the device-only control arm, supporting a drug-driven mechanism of action.